{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:59:00Z","timestamp":1790834340744,"version":"4.1.0"},"reference-count":193,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,1,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Allogeneic hematopoietic stem cell transplantation (alloHSCT) is a potentially curative treatment for patients with high-risk acute leukemias, but unfortunately disease recurrence remains the major cause of death in these patients. Infusion of donor lymphocytes (DLI) has the potential to restore graft-versus-leukemia immunologic surveillance; however, efficacy varies across different hematologic entities. Although relapsed chronic myeloid leukemia, transplanted in chronic phase, has proven remarkably susceptible to DLI, response rates are more modest for relapsed acute myeloid leukemia and acute lymphoblastic leukemia. To prevent impending relapse, a number of groups have explored administering DLI preemptively on detection of measurable residual disease (MRD) or mixed chimerism. Evidence for the effectiveness of this strategy, although encouraging, comes from only a few, mostly single-center retrospective, nonrandomized studies. This article seeks to (1) discuss the available evidence supporting this approach while highlighting some of the inherent challenges of MRD-triggered treatment decisions post-transplant, (2) portray other forms of postremission cellular therapies, including the role of next-generation target-specific immunotherapies, and (3) provide a practical framework to support clinicians in their decision-making process when considering preemptive cellular therapy for this difficult-to-treat patient population.<\/jats:p>","DOI":"10.1182\/blood.2021012411","type":"journal-article","created":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T19:00:38Z","timestamp":1651777238000},"page":"22-38","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":43,"title":["How I treat high-risk acute myeloid leukemia using preemptive adoptive cellular immunotherapy"],"prefix":"10.1182","volume":"141","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2805-8231","authenticated-orcid":false,"given":"Alexander","family":"Biederst\u00e4dt","sequence":"first","affiliation":[{"name":"1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX"},{"name":"2Department of Medicine III: Hematology and Oncology, School of Medicine, Technical University of Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9599-2246","authenticated-orcid":false,"given":"Katayoun","family":"Rezvani","sequence":"additional","affiliation":[{"name":"1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"11","key":"2023082419243871700_bib1","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1038\/bmt.2016.167","article-title":"Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT","volume":"51","author":"Tsirigotis","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"2023082419243871700_bib2","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.bbmt.2019.04.010","article-title":"Blinatumomab for acute lymphoblastic leukemia relapse after allogeneic hematopoietic stem cell transplantation","volume":"25","author":"Stein","year":"2019","journal-title":"Biol\u00a0Blood Marrow Transplant"},{"issue":"6","key":"2023082419243871700_bib3","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1038\/leu.2011.351","article-title":"Immunotherapy Subcommittee of Acute Leukemia Working Party. Outcomes and prognostic factors of adults with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic cell transplantation. An analysis on behalf of the\u00a0Acute Leukemia Working Party of EBMT","volume":"26","author":"Spyridonidis","year":"2012","journal-title":"Leukemia"},{"issue":"31","key":"2023082419243871700_bib4","doi-asserted-by":"crossref","first-page":"4938","DOI":"10.1200\/JCO.2007.11.6053","article-title":"EBMT Acute Leukemia Working Party. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party","volume":"25","author":"Schmid","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"2023082419243871700_bib5","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1001\/jamaoncol.2018.2091","article-title":"Association of second allogeneic hematopoietic cell transplant vs donor lymphocyte infusion with overall survival in patients with acute myeloid leukemia relapse","volume":"4","author":"Kharfan-Dabaja","year":"2018","journal-title":"JAMA Oncol"},{"issue":"12","key":"2023082419243871700_bib6","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1182\/blood.V76.12.2462.2462","article-title":"Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients","volume":"76","author":"Kolb","year":"1990","journal-title":"Blood"},{"issue":"5","key":"2023082419243871700_bib7","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1182\/blood.V86.5.2041.bloodjournal8652041","article-title":"European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients","volume":"86","author":"Kolb","year":"1995","journal-title":"Blood"},{"issue":"9","key":"2023082419243871700_bib8","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1182\/blood-2013-08-523001","article-title":"Reversal of in situ T-cell exhaustion during effective human antileukemia responses to donor lymphocyte infusion","volume":"123","author":"Bachireddy","year":"2014","journal-title":"Blood"},{"issue":"3","key":"2023082419243871700_bib9","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/bmt.2009.177","article-title":"Chronic Leukemia Working Party of European Group for Blood and Marrow Transplantation. Outcome of patients developing GVHD after DLI given to treat CML relapse: a study by the Chronic Leukemia Working Party of the EBMT","volume":"45","author":"Chalandon","year":"2010","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"2023082419243871700_bib10","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1016\/j.bbmt.2014.07.010","article-title":"Donor lymphocyte infusion for the treatment of relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: a retrospective analysis by the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation","volume":"20","author":"Takami","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"2023082419243871700_bib11","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/sj.bmt.1702555","article-title":"Donor leukocyte infusions in acute lymphocytic leukemia","volume":"26","author":"Collins","year":"2000","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"2023082419243871700_bib12","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.3390\/cancers13061481","article-title":"Arming immune cells for battle: a brief journey through the advancements of T and NK cell immunotherapy","volume":"13","author":"Wendel","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"17","key":"2023082419243871700_bib13","doi-asserted-by":"crossref","first-page":"4373","DOI":"10.1158\/0008-5472.CAN-21-0301","article-title":"60 years young:\u00a0the evolving role of allogeneic hematopoietic stem cell transplantation in cancer immunotherapy","volume":"81","author":"Cieri","year":"2021","journal-title":"Cancer Res"},{"issue":"5","key":"2023082419243871700_bib14","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/bmt.2015.234","article-title":"Long-term results of adjuvant donor lymphocyte transfusion in AML after allogeneic stem cell transplantation","volume":"51","author":"Jedlickova","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"2023082419243871700_bib15","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.bbmt.2017.04.028","article-title":"Prophylactic donor lymphocyte infusion (DLI) followed by minimal residual disease and graft-versus-host disease-guided multiple DLIs could improve outcomes after allogeneic hematopoietic stem cell transplantation in patients with refractory\/relapsed acute leukemia [published correction appears in Biol Blood Marrow Transplant. 2020;26(1):214]","volume":"23","author":"Yan","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2023082419243871700_bib16","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/bjh.15544","article-title":"Prophylactic donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation for high risk haematological malignancies: a retrospective bicentric analysis of serial infusions of increasing doses of CD3+ cells","volume":"185","author":"Cauchois","year":"2019","journal-title":"Br J Haematol"},{"issue":"1","key":"2023082419243871700_bib17","first-page":"E39","article-title":"Immunological and clinical impact of manipulated and unmanipulated DLI after allogeneic stem cell transplantation of AML patients","volume":"9","author":"Greiner","year":"2019","journal-title":"J\u00a0Clin Med"},{"issue":"1","key":"2023082419243871700_bib18","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00277-018-3482-7","article-title":"Donor lymphocyte infusion for prevention of relapse after unmanipulated haploidentical PBSCT for very high-risk hematologic malignancies","volume":"98","author":"Gao","year":"2019","journal-title":"Ann Hematol"},{"issue":"5","key":"2023082419243871700_bib19","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/bjh.15691","article-title":"EBMT Acute Leukaemia Working Party. Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation in acute leukaemia - a matched pair analysis by the Acute Leukaemia Working Party of EBMT","volume":"184","author":"Schmid","year":"2019","journal-title":"Br J Haematol"},{"issue":"11","key":"2023082419243871700_bib20","doi-asserted-by":"crossref","first-page":"5063","DOI":"10.1182\/blood-2007-02-072470","article-title":"Donor lymphocyte infusions for the treatment of minimal residual disease in acute leukemia","volume":"109","author":"Dominietto","year":"2007","journal-title":"Blood"},{"issue":"21","key":"2023082419243871700_bib21","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.1182\/blood.V118.21.4311.4311","article-title":"Preemptive donor lymphocyte infusion induces polyspecific T-cell responses in a patient with AML with NPM1 Mutation","volume":"118","author":"Hofmann","year":"2011","journal-title":"Blood"},{"issue":"14","key":"2023082419243871700_bib22","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1182\/blood-2011-09-380386","article-title":"Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic\u00a0hematopoietic stem cell transplantation","volume":"119","author":"Yan","year":"2012","journal-title":"Blood"},{"issue":"12","key":"2023082419243871700_bib23","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1182\/blood-2014-03-563403","article-title":"In adults with t(8;21)AML, posttransplant RUNX1\/RUNX1T1-based MRD monitoring, rather than c-KIT mutations, allows further risk stratification","volume":"124","author":"Wang","year":"2014","journal-title":"Blood"},{"issue":"5","key":"2023082419243871700_bib24","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/bmt.2014.2","article-title":"Preemptive DLI without withdrawal of immunosuppression to promote complete donor T-cell chimerism results in favorable outcomes for high-risk older recipients of alemtuzumab-containing reduced-intensity unrelated donor allogeneic transplant: a prospective phase II trial","volume":"49","author":"Solomon","year":"2014","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2023082419243871700_bib25","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.bbmt.2013.11.020","article-title":"HLA-haploidentical donor lymphocyte infusions for patients with relapsed hematologic malignancies after related HLA-haploidentical bone marrow transplantation","volume":"20","author":"Zeidan","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2023082419243871700_bib26","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/bmt.2014.217","article-title":"DLI after haploidentical BMT with post-transplant CY","volume":"50","author":"Ghiso","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"2023082419243871700_bib27","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s00277-017-2960-7","article-title":"Comparison of outcomes after donor lymphocyte infusion with or without prior chemotherapy for minimal residual disease in acute leukemia\/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation","volume":"96","author":"Mo","year":"2017","journal-title":"Ann Hematol"},{"issue":"12","key":"2023082419243871700_bib28","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1038\/bmt.2017.193","article-title":"Donor-lymphocyte infusion following haploidentical hematopoietic cell transplantation with peripheral blood stem cell grafts and PTCy","volume":"52","author":"Goldsmith","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"2023082419243871700_bib29","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1007\/s00277-021-04494-z","article-title":"Donor lymphocyte infusions after first allogeneic hematopoietic stem-cell transplantation in adults with acute myeloid leukemia: a single-center landmark analysis","volume":"100","author":"Rettig","year":"2021","journal-title":"Ann Hematol"},{"issue":"6","key":"2023082419243871700_bib30","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1111\/trf.12524","article-title":"Superiority of preemptive donor lymphocyte infusion based on minimal residual disease in acute leukemia patients after allogeneic hematopoietic stem cell transplantation","volume":"54","author":"Tan","year":"2014","journal-title":"Transfusion"},{"issue":"11","key":"2023082419243871700_bib31","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/j.bbmt.2017.07.007","article-title":"Donor lymphocyte infusions used to treat mixed-chimeric and high-risk patient populations in the relapsed and nonrelapsed settings after allogeneic transplantation for hematologic malignancies are associated with high five-year survival if persistent full donor chimerism is obtained or maintained","volume":"23","author":"Caldemeyer","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"2023082419243871700_bib32","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/sj.bmt.1705898","article-title":"Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation","volume":"41","author":"Loren","year":"2008","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2023082419243871700_bib33","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.transci.2016.05.011","article-title":"Donor lymphocyte infusion after allogeneic stem cell transplantation","volume":"54","author":"Castagna","year":"2016","journal-title":"Transfus Apheresis Sci"},{"issue":"2","key":"2023082419243871700_bib34","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41409-021-01515-3","article-title":"Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia","volume":"57","author":"Schmid","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"2023082419243871700_bib35","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/j.bbmt.2016.03.005","article-title":"Wilms tumor 1 expression and pre-emptive immunotherapy in patients with acute myeloid leukemia undergoing an allogeneic hemopoietic stem cell transplantation","volume":"22","author":"Di Grazia","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"2023082419243871700_bib36","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.3390\/cancers13112699","article-title":"Repetitively administered low-dose donor lymphocyte infusion for prevention of relapse after allogeneic stem cell transplantation in patients with high-risk acute leukemia","volume":"13","author":"Tsirigotis","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"19","key":"2023082419243871700_bib37","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1182\/blood.2019003566","article-title":"How I treat measurable (minimal) residual disease in acute leukemia after allogeneic hematopoietic cell transplantation","volume":"135","author":"Spyridonidis","year":"2020","journal-title":"Blood"},{"key":"2023082419243871700_bib38","volume-title":"The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies","year":"2019"},{"issue":"1","key":"2023082419243871700_bib39","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3324\/haematol.2019.219790","article-title":"Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT","volume":"105","author":"Dholaria","year":"2020","journal-title":"Haematologica"},{"issue":"11","key":"2023082419243871700_bib40","doi-asserted-by":"crossref","first-page":"4337","DOI":"10.1182\/blood.V86.11.4337.bloodjournal86114337","article-title":"CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation","volume":"86","author":"Giralt","year":"1995","journal-title":"Blood"},{"issue":"10","key":"2023082419243871700_bib41","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1182\/blood.V91.10.3671","article-title":"Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant","volume":"91","author":"Alyea","year":"1998","journal-title":"Blood"},{"issue":"11","key":"2023082419243871700_bib42","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1053\/bbmt.2002.v8.abbmt080625","article-title":"Randomized trial of CD8+ T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion","volume":"8","author":"Soiffer","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"2023082419243871700_bib43","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1097\/TP.0b013e3181bbf382","article-title":"Phase I study of high-stringency CD8 depletion of donor leukocyte infusions after allogeneic hematopoietic stem cell transplantation","volume":"88","author":"Orti","year":"2009","journal-title":"Transplantation"},{"issue":"1","key":"2023082419243871700_bib44","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1182\/blood-2006-03-005769","article-title":"Prophylactic transfer of CD8-depleted donor lymphocytes after T-cell-depleted reduced-intensity transplantation","volume":"109","author":"Meyer","year":"2007","journal-title":"Blood"},{"issue":"19","key":"2023082419243871700_bib45","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1182\/blood-2008-10-183723","article-title":"Haploidentical stem cell transplantation after a reduced-intensity conditioning regimen for the treatment of advanced hematologic malignancies: posttransplantation CD8-depleted donor lymphocyte infusions contribute to improve T-cell recovery","volume":"113","author":"Dodero","year":"2009","journal-title":"Blood"},{"issue":"9","key":"2023082419243871700_bib46","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1097\/CJI.0b013e318184908d","article-title":"Donor regulatory T cells identified by FoxP3 expression but also by the membranous CD4+CD127low\/neg phenotype influence graft-versus-tumor effect after donor lymphocyte infusion","volume":"31","author":"Hicheri","year":"2008","journal-title":"J Immunother"},{"issue":"41","key":"2023082419243871700_bib47","doi-asserted-by":"crossref","first-page":"41ra52","DOI":"10.1126\/scitranslmed.3001302","article-title":"CD4+CD25+ regulatory T cell depletion improves the graft-versus-tumor effect of donor lymphocytes after allogeneic hematopoietic stem cell transplantation","volume":"2","author":"Maury","year":"2010","journal-title":"Sci Transl Med"},{"issue":"10","key":"2023082419243871700_bib48","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.3324\/haematol.2015.141176","article-title":"A\u00a0phase I study of CD25\/regulatory T-cell-depleted donor lymphocyte infusion for relapse after allogeneic stem cell transplantation","volume":"101","author":"Nikiforow","year":"2016","journal-title":"Haematologica"},{"issue":"1","key":"2023082419243871700_bib49","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1172\/JCI17601","article-title":"Memory CD4+ T cells do not induce graft-versus-host disease","volume":"112","author":"Anderson","year":"2003","journal-title":"J\u00a0Clin Invest"},{"issue":"6","key":"2023082419243871700_bib50","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1182\/blood-2010-10-310599","article-title":"Engraftment of human central memory-derived effector CD8+ T cells in immunodeficient mice","volume":"117","author":"Wang","year":"2011","journal-title":"Blood"},{"issue":"6","key":"2023082419243871700_bib51","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1182\/bloodadvances.2017012104","article-title":"Infusion of donor-derived CD8+ memory T\u00a0cells for relapse following allogeneic hematopoietic cell transplantation","volume":"2","author":"Muffly","year":"2018","journal-title":"Blood Adv"},{"issue":"2 suppl 2","key":"2023082419243871700_bib52","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1038\/bmt.2015.87","article-title":"Improved immune recovery after transplantation of TCR\u03b1\u03b2\/CD19-depleted allografts from haploidentical donors in pediatric patients","volume":"50","author":"Lang","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"2023082419243871700_bib53","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1182\/blood-2017-04-779769","article-title":"Outcome of children with acute leukemia given HLA-haploidentical HSCT after \u03b1\u03b2 T-cell and B-cell depletion","volume":"130","author":"Locatelli","year":"2017","journal-title":"Blood"},{"key":"2023082419243871700_bib54","first-page":"214","article-title":"Safety and efficacy of Tcralpha\/beta and CD19 depleted haploidentical stem cell transplantation following reduced intensity conditioning in children: results of a prospective multicenter phase I\/II clinical trial","volume":"130","author":"Lang","year":"2017","journal-title":"Blood"},{"issue":"24","key":"2023082419243871700_bib55","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1182\/blood-2018-07-861575","article-title":"Unrelated donor vs HLA-haploidentical \u03b1\/\u03b2 T-cell- and B-cell-depleted HSCT in children with acute leukemia","volume":"132","author":"Bertaina","year":"2018","journal-title":"Blood"},{"issue":"12","key":"2023082419243871700_bib56","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1038\/bmt.2017.185","article-title":"\u03b1\u03b2-T-cell depleted donor lymphocyte infusion for leukemia relapse after allogeneic stem cell transplantation","volume":"52","author":"Kordelas","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"5 suppl","key":"2023082419243871700_bib57","doi-asserted-by":"crossref","first-page":"S134","DOI":"10.1016\/j.jcyt.2020.03.262","article-title":"Manufacturing a donor lymphocyte product depleted of TCR-\u03b1\u03b2 T cells and CD19+ B cells for prophylactic infusion following allogeneic stem cell transplantation","volume":"22","author":"Otegbeye","year":"2020","journal-title":"Cytotherapy"},{"issue":"7","key":"2023082419243871700_bib58","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1038\/s41375-020-0733-0","article-title":"ATIR101 administered after T-cell-depleted haploidentical HSCT reduces NRM and improves overall survival in acute leukemia","volume":"34","author":"Roy","year":"2020","journal-title":"Leukemia"},{"issue":"4","key":"2023082419243871700_bib59","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1182\/blood-2005-08-3373","article-title":"A\u00a0phase 1 trial of donor lymphocyte infusions expanded and activated ex\u00a0vivo via CD3\/CD28 costimulation","volume":"107","author":"Porter","year":"2006","journal-title":"Blood"},{"issue":"7","key":"2023082419243871700_bib60","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.bbmt.2013.04.021","article-title":"Pilot study of prophylactic ex\u00a0vivo costimulated donor leukocyte infusion after reduced-intensity conditioned allogeneic stem cell transplantation [published correction appears in Biol Blood Marrow Transplant. 2015;125(16):2583]","volume":"19","author":"Kumar","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"2023082419243871700_bib61","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1182\/blood-2003-06-2125","article-title":"Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells [published correction appears in Blood. 2015;125(16):2583]","volume":"103","author":"Verneris","year":"2004","journal-title":"Blood"},{"issue":"6","key":"2023082419243871700_bib62","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1182\/blood-2007-06-092817","article-title":"In\u00a0vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity","volume":"112","author":"Nishimura","year":"2008","journal-title":"Blood"},{"issue":"11","key":"2023082419243871700_bib63","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1016\/j.bbmt.2011.05.012","article-title":"Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation","volume":"17","author":"Laport","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"2023082419243871700_bib64","doi-asserted-by":"crossref","first-page":"952","DOI":"10.3324\/haematol.11132","article-title":"Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study","volume":"92","author":"Introna","year":"2007","journal-title":"Haematologica"},{"issue":"3","key":"2023082419243871700_bib65","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/bmt.2012.144","article-title":"G-CSF mobilized vs conventional donor lymphocytes for therapy of relapse or incomplete engraftment after allogeneic hematopoietic transplantation","volume":"48","author":"Abbi","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"22","key":"2023082419243871700_bib66","doi-asserted-by":"crossref","first-page":"5809","DOI":"10.1182\/blood.V128.22.5809.5809","article-title":"Efficacy of G-CSF primed DLI using cells reserved at the time of harvest in patients with hematologic malignancies who lately relapsed after allogeneic PBSCT","volume":"128","author":"Lee","year":"2016","journal-title":"Blood"},{"issue":"1","key":"2023082419243871700_bib67","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/bjh.15881","article-title":"G-CSF administration prior to donor lymphocyte apheresis promotes anti-leukaemic effects in allogeneic HCT patients","volume":"186","author":"Schneidawind","year":"2019","journal-title":"Br J Haematol"},{"issue":"7","key":"2023082419243871700_bib68","first-page":"E2204","article-title":"A\u00a0retrospective comparison of DLI and gDLI for post-transplant treatment","volume":"9","author":"Lamure","year":"2020","journal-title":"J\u00a0Clin Med"},{"issue":"3 suppl","key":"2023082419243871700_bib69","doi-asserted-by":"crossref","first-page":"S171","DOI":"10.1016\/j.bbmt.2018.12.312","article-title":"Donor lymphocyte infusion from G-CSF-primed, unmanipulated whole blood is safe and improves chimerism in HLA-matched and haploidentical transplantation","volume":"25","author":"De Le\u00f3n","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2023082419243871700_bib70","doi-asserted-by":"crossref","first-page":"414","DOI":"10.3324\/haematol.10570","article-title":"Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched\/haploidentical T-cell-replete hematopoietic stem cell transplantation","volume":"92","author":"Huang","year":"2007","journal-title":"Haematologica"},{"issue":"6","key":"2023082419243871700_bib71","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1016\/j.jcyt.2015.03.505","article-title":"G-CSF primed donor haematopoietic stem cell collections are associated with reduced viable T cell yield for donor lymphocyte infusion","volume":"17","author":"Antonenas","year":"2015","journal-title":"Cytotherapy"},{"issue":"10","key":"2023082419243871700_bib72","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1016\/j.bbmt.2016.07.016","article-title":"Improved outcome of refractory\/relapsed acute myeloid leukemia after post-transplantation cyclophosphamide-based haploidentical transplantation with myeloablative conditioning and early prophylactic granulocyte colony-stimulating factor-mobilized donor lymphocyte infusions","volume":"22","author":"Jaiswal","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"2023082419243871700_bib73","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/S1525-0016(16)37470-6","article-title":"29. Multi-tumor-antigen-specific cytotoxic T lymphocytes for cancer immunotherapy","volume":"18","author":"Gerdemann","year":"2010","journal-title":"Mol Ther"},{"issue":"7","key":"2023082419243871700_bib74","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1038\/leu.2013.66","article-title":"Generation of multi-leukemia antigen-specific T cells to enhance the graft-versus-leukemia effect after allogeneic stem cell transplant","volume":"27","author":"Weber","year":"2013","journal-title":"Leukemia"},{"issue":"21","key":"2023082419243871700_bib75","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1182\/blood.V118.21.2985.2985","article-title":"Generation of multi-antigen specific T cells for adoptive immunotherapy of myeloid leukemia and identification of MHC class I and II-restricted peptides for WT1, proteinase 3 and human neutrophil elastase","volume":"118","author":"Weber","year":"2011","journal-title":"Blood"},{"issue":"174","key":"2023082419243871700_bib76","doi-asserted-by":"crossref","first-page":"174ra27","DOI":"10.1126\/scitranslmed.3004916","article-title":"Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients","volume":"5","author":"Chapuis","year":"2013","journal-title":"Sci Transl Med"},{"issue":"19","key":"2023082419243871700_bib77","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1182\/blood.2020009471","article-title":"Clinical effects of administering leukemia-specific donor T cells to patients with AML\/MDS after allogeneic transplant [published correction appears in Blood. 2022;139(8):1257]","volume":"137","author":"Lulla","year":"2021","journal-title":"Blood"},{"issue":"11","key":"2023082419243871700_bib78","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1182\/blood-2009-11-249474","article-title":"Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia","volume":"116","author":"Goodyear","year":"2010","journal-title":"Blood"},{"issue":"12","key":"2023082419243871700_bib79","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1182\/blood-2008-05-158956","article-title":"Hypomethylating drugs convert HA-1-negative solid tumors into targets for stem cell-based immunotherapy","volume":"113","author":"Hambach","year":"2009","journal-title":"Blood"},{"issue":"12","key":"2023082419243871700_bib80","doi-asserted-by":"crossref","first-page":"3847","DOI":"10.1182\/blood.V96.12.3847","article-title":"Up-regulation of costimulatory\/adhesion molecules by histone deacetylase inhibitors in acute myeloid leukemia cells","volume":"96","author":"Maeda","year":"2000","journal-title":"Blood"},{"issue":"12","key":"2023082419243871700_bib81","doi-asserted-by":"crossref","first-page":"7017","DOI":"10.4049\/jimmunol.165.12.7017","article-title":"Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors","volume":"165","author":"Magner","year":"2000","journal-title":"J\u00a0Immunol"},{"issue":"23","key":"2023082419243871700_bib82","doi-asserted-by":"crossref","first-page":"11136","DOI":"10.1158\/0008-5472.CAN-05-0599","article-title":"Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B","volume":"65","author":"Skov","year":"2005","journal-title":"Cancer Res"},{"issue":"9","key":"2023082419243871700_bib83","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1038\/leu.2013.64","article-title":"Salvage therapy with azacitidine increases regulatory T cells in peripheral blood of patients with AML or MDS and early relapse after allogeneic blood stem cell transplantation","volume":"27","author":"Schroeder","year":"2013","journal-title":"Leukemia"},{"issue":"1","key":"2023082419243871700_bib84","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1182\/blood-2009-12-257253","article-title":"In\u00a0vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia","volume":"116","author":"Choi","year":"2010","journal-title":"Blood"},{"issue":"14","key":"2023082419243871700_bib85","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1182\/blood-2011-09-377044","article-title":"Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML)","volume":"119","author":"Goodyear","year":"2012","journal-title":"Blood"},{"issue":"5","key":"2023082419243871700_bib86","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/bmt.2015.10","article-title":"5-Azacytidine and DLI can induce long-term remissions in AML patients relapsed after allograft","volume":"50","author":"Steinmann","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"2023082419243871700_bib87","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/bmt.2013.233","article-title":"Azacitidine salvage therapy for relapse of myeloid malignancies following allogeneic hematopoietic SCT","volume":"49","author":"Tessoulin","year":"2014","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"2023082419243871700_bib88","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1038\/leu.2013.7","article-title":"Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation","volume":"27","author":"Schroeder","year":"2013","journal-title":"Leukemia"},{"issue":"11","key":"2023082419243871700_bib89","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1038\/s41409-019-0536-y","article-title":"Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndrome","volume":"54","author":"Guillaume","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"23","key":"2023082419243871700_bib90","doi-asserted-by":"crossref","first-page":"4344","DOI":"10.1182\/blood.V126.23.4344.4344","article-title":"Phase I\/II study of the deacetylase inhibitor panobinostat as maintenance therapy after an allogeneic stem cell transplantation in patients with high-risk MDS or AML: the Panobest-Trial","volume":"126","author":"Bug","year":"2015","journal-title":"Blood"},{"issue":"18","key":"2023082419243871700_bib91","doi-asserted-by":"crossref","first-page":"4430","DOI":"10.1182\/bloodadvances.2020002074","article-title":"Panobinostat and decitabine prior to donor lymphocyte infusion in allogeneic stem cell transplantation","volume":"4","author":"Kalin","year":"2020","journal-title":"Blood Adv"},{"issue":"21","key":"2023082419243871700_bib92","doi-asserted-by":"crossref","first-page":"5580","DOI":"10.1182\/bloodadvances.2020002544","article-title":"A\u00a0phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients [published correction appears in Blood Adv. 2021;5(6):1755\u20131756]","volume":"4","author":"Oran","year":"2020","journal-title":"Blood Adv"},{"issue":"3","key":"2023082419243871700_bib93","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/nm.4484","article-title":"Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells [published correction appears in Nat Med. 2018;24(4):526]","volume":"24","author":"Mathew","year":"2018","journal-title":"Nat Med"},{"issue":"3","key":"2023082419243871700_bib94","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s00277-021-04398-y","article-title":"Venetoclax and donor lymphocyte infusion for early relapsed acute myeloid leukemia after allogeneic hematopoietic cell transplantation. A retrospective multicenter trial","volume":"100","author":"Amit","year":"2021","journal-title":"Ann Hematol"},{"issue":"9","key":"2023082419243871700_bib95","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1038\/bmt.2016.104","article-title":"Concurrent blinatumomab and donor lymphocyte infusions for treatment of relapsed pre-B-cell ALL after allogeneic hematopoietic cell transplant","volume":"51","author":"Ueda","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"suppl 1","key":"2023082419243871700_bib96","first-page":"2604","article-title":"The efficacy and toxicity of blinatumomab in patients with relapsed\/refractory acute lymphoblastic leukemia: Russian Multicenter Experience","volume":"130","author":"Bondarenko","year":"2017","journal-title":"Blood"},{"issue":"suppl 1","key":"2023082419243871700_bib97","doi-asserted-by":"crossref","first-page":"5742","DOI":"10.1182\/blood-2018-99-109998","article-title":"Concomitant use of blinatumomab and donor lymphocyte infusion for post-transplant relapsed CD19 positive acute lymphoblastic leukemia: systematic review","volume":"132","author":"Durer","year":"2018","journal-title":"Blood"},{"issue":"3","key":"2023082419243871700_bib98","first-page":"166","article-title":"Treatment of relapsed\/refractory acute lymphoblastic leukemia","volume":"17","author":"Paul","year":"2019","journal-title":"Clin Adv Hematol Oncol"},{"key":"2023082419243871700_bib99","doi-asserted-by":"crossref","first-page":"S161","DOI":"10.1016\/S2152-2650(20)30678-9","article-title":"ALL-073: inotuzumab ozogamicin (IO) and donor lymphocyte infusion (DLI) are a safe and promising combination in relapsed acute lymphoblastic leukemia (ALL) after allogeneic hematopoietic stem cell transplant (HSCT)","volume":"20","author":"Papayannidis","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"2023082419243871700_bib100","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1056\/NEJMoa1601202","article-title":"Leukemia and Lymphoma Society Blood Cancer Research Partnership. Ipilimumab for patients with relapse after allogeneic transplantation","volume":"375","author":"Davids","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"567","key":"2023082419243871700_bib101","doi-asserted-by":"crossref","first-page":"eabb8969","DOI":"10.1126\/scitranslmed.abb8969","article-title":"Metabolic reprogramming of donor T cells enhances graft-versus-leukemia effects in mice and humans","volume":"12","author":"Uhl","year":"2020","journal-title":"Sci Transl Med"},{"issue":"12","key":"2023082419243871700_bib102","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1182\/blood-2018-10-846824","article-title":"Mechanisms of immune escape after allogeneic hematopoietic cell transplantation","volume":"133","author":"Zeiser","year":"2019","journal-title":"Blood"},{"issue":"5","key":"2023082419243871700_bib103","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1056\/NEJMoa0811036","article-title":"Loss of mismatched HLA in leukemia after stem-cell transplantation","volume":"361","author":"Vago","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"2023082419243871700_bib104","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1182\/blood-2009-11-254284","article-title":"Relapse of leukemia with loss of mismatched HLA resulting from uniparental disomy after haploidentical hematopoietic stem cell transplantation","volume":"115","author":"Villalobos","year":"2010","journal-title":"Blood"},{"issue":"10","key":"2023082419243871700_bib105","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1038\/leu.2016.144","article-title":"Loss of the mismatched human leukocyte antigen haplotype in two acute myelogenous leukemia relapses after haploidentical bone marrow transplantation with post-transplantation cyclophosphamide","volume":"30","author":"McCurdy","year":"2016","journal-title":"Leukemia"},{"issue":"4","key":"2023082419243871700_bib106","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/bmt.2016.324","article-title":"Acquired uniparental disomy in chromosome 6p as a feature of relapse after T-cell replete haploidentical hematopoietic stem cell transplantation using cyclophosphamide tolerization","volume":"52","author":"Grosso","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"24","key":"2023082419243871700_bib107","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1056\/NEJMoa1808777","article-title":"Immune escape of relapsed AML cells after allogeneic transplantation","volume":"379","author":"Christopher","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"2023082419243871700_bib108","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41591-019-0400-z","article-title":"Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation","volume":"25","author":"Toffalori","year":"2019","journal-title":"Nat Med"},{"issue":"5562","key":"2023082419243871700_bib109","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1126\/science.1068440","article-title":"Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants","volume":"295","author":"Ruggeri","year":"2002","journal-title":"Science"},{"issue":"1","key":"2023082419243871700_bib110","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1182\/blood-2006-07-038687","article-title":"Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value","volume":"110","author":"Ruggeri","year":"2007","journal-title":"Blood"},{"issue":"6","key":"2023082419243871700_bib111","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/MOH.0b013e3283590395","article-title":"Natural killer cell alloreactivity 10 years later","volume":"19","author":"Velardi","year":"2012","journal-title":"Curr Opin Hematol"},{"issue":"3","key":"2023082419243871700_bib112","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.bcmd.2004.08.013","article-title":"IL-2 activated NK cell immunotherapy of three children after haploidentical stem cell transplantation","volume":"33","author":"Koehl","year":"2004","journal-title":"Blood Cells Mol Dis"},{"issue":"11","key":"2023082419243871700_bib113","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1038\/sj.leu.2403524","article-title":"Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation","volume":"18","author":"Passweg","year":"2004","journal-title":"Leukemia"},{"issue":"14 suppl","key":"2023082419243871700_bib114","doi-asserted-by":"crossref","first-page":"6516","DOI":"10.1200\/jco.2004.22.90140.6516","article-title":"Use of matched or mismatched rIL-2 activated donor lymphocytes positively selected for CD56+ for immunotherapy of resistant leukemia after allogeneic stem cell transplantation","volume":"22","author":"Slavin","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"2023082419243871700_bib115","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1055\/s-2005-872520","article-title":"Ex\u00a0vivo expansion of highly purified NK cells for immunotherapy after haploidentical stem cell transplantation in children","volume":"217","author":"Koehl","year":"2005","journal-title":"Klin Padiatr"},{"issue":"4","key":"2023082419243871700_bib116","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.beha.2006.06.004","article-title":"Natural-killer-cell-based treatment in haematopoietic stem-cell transplantation","volume":"19","author":"Passweg","year":"2006","journal-title":"Best Pract Res Clin Haematol"},{"issue":"5","key":"2023082419243871700_bib117","doi-asserted-by":"crossref","first-page":"753","DOI":"10.2217\/imt.09.47","article-title":"Safety analysis of ex\u00a0vivo-expanded NK and NK-like T cells administered to cancer patients: a phase I clinical study","volume":"1","author":"Barkholt","year":"2009","journal-title":"Immunotherapy"},{"issue":"8","key":"2023082419243871700_bib118","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.bbmt.2010.02.018","article-title":"Natural killer cell-enriched donor lymphocyte infusions from A 3-6\/6 HLA matched family member following nonmyeloablative allogeneic stem cell transplantation","volume":"16","author":"Rizzieri","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"21","key":"2023082419243871700_bib119","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1182\/blood.V116.21.2370.2370","article-title":"Successful treatment of high-risk and refractory acute myeloid leukemia with haploidentical stem cell transplantation plus NK cell therapy","volume":"116","author":"Uharek","year":"2010","journal-title":"Blood"},{"issue":"3","key":"2023082419243871700_bib120","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2217\/imt.11.174","article-title":"NK cell therapy: targeting disease relapse after hematopoietic stem cell transplantation","volume":"4","author":"Farhan","year":"2012","journal-title":"Immunotherapy"},{"issue":"7","key":"2023082419243871700_bib121","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/j.bbmt.2016.04.009","article-title":"Haploidentical natural killer cells infused before allogeneic stem cell transplantation for myeloid malignancies: a phase I trial","volume":"22","author":"Lee","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"suppl 1","key":"2023082419243871700_bib122","first-page":"8","article-title":"Cytokine-induced memory-like NK cells exhibit massive expansion and long-term persistence after infusion post-haploidentical stem cell transplantation: a report of the first three cases in a phase I trial","volume":"136","author":"Shapiro","year":"2020","journal-title":"Blood"},{"issue":"24","key":"2023082419243871700_bib123","doi-asserted-by":"crossref","first-page":"4751","DOI":"10.1182\/blood-2012-04-419283","article-title":"Cytokine activation induces human memory-like NK cells","volume":"120","author":"Romee","year":"2012","journal-title":"Blood"},{"issue":"357","key":"2023082419243871700_bib124","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf2341","article-title":"Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia","volume":"8","author":"Romee","year":"2016","journal-title":"Sci Transl Med"},{"issue":"16","key":"2023082419243871700_bib125","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2017-05-785659","article-title":"Phase 1 clinical trial using mbIL21 ex\u00a0vivo-expanded donor-derived NK cells after haploidentical transplantation [published correction appears in Blood. 2018;132(26):2782]","volume":"130","author":"Ciurea","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2023082419243871700_bib126","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41375-021-01349-4","article-title":"Decrease post-transplant relapse using donor-derived expanded NK-cells","volume":"36","author":"Ciurea","year":"2022","journal-title":"Leukemia"},{"issue":"25","key":"2023082419243871700_bib127","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1182\/blood-2014-01-551671","article-title":"Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene","volume":"123","author":"Zhou","year":"2014","journal-title":"Blood"},{"issue":"26","key":"2023082419243871700_bib128","doi-asserted-by":"crossref","first-page":"4103","DOI":"10.1182\/blood-2015-02-628354","article-title":"Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation","volume":"125","author":"Zhou","year":"2015","journal-title":"Blood"},{"issue":"5","key":"2023082419243871700_bib129","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(09)70074-9","article-title":"Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study","volume":"10","author":"Ciceri","year":"2009","journal-title":"Lancet Oncol"},{"issue":"25","key":"2023082419243871700_bib130","doi-asserted-by":"crossref","first-page":"4129","DOI":"10.1182\/blood-2013-08-519413","article-title":"Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation","volume":"122","author":"Kochenderfer","year":"2013","journal-title":"Blood"},{"issue":"10","key":"2023082419243871700_bib131","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2015.64.5929","article-title":"Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease","volume":"34","author":"Brudno","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"2023082419243871700_bib132","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.3324\/haematol.2010.026310","article-title":"Cytokine-induced killer cells for cell therapy of acute myeloid leukemia: improvement of their immune activity by expression of CD33-specific chimeric receptors","volume":"95","author":"Marin","year":"2010","journal-title":"Haematologica"},{"key":"2023082419243871700_bib133","doi-asserted-by":"crossref","first-page":"683065","DOI":"10.1155\/2012\/683065","article-title":"In\u00a0vitro and in\u00a0vivo antitumor effect of anti-cd33 chimeric receptor-expressing EBV-CTL against acute myeloid leukemia","volume":"2012","author":"Dutour","year":"2012","journal-title":"Adv Hematol"},{"issue":"1","key":"2023082419243871700_bib134","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/mt.2014.164","article-title":"Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia","volume":"23","author":"Wang","year":"2015","journal-title":"Mol Ther"},{"issue":"8","key":"2023082419243871700_bib135","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1038\/leu.2014.62","article-title":"Chimeric antigen receptors against CD33\/CD123 antigens efficiently target primary acute myeloid leukemia cells in\u00a0vivo","volume":"28","author":"Pizzitola","year":"2014","journal-title":"Leukemia"},{"issue":"11","key":"2023082419243871700_bib136","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1038\/s41375-021-01232-2","article-title":"Autologous CD33-CAR-T cells for treatment of relapsed\/refractory acute myelogenous leukemia","volume":"35","author":"Tambaro","year":"2021","journal-title":"Leukemia"},{"issue":"18","key":"2023082419243871700_bib137","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1182\/blood-2012-12-474056","article-title":"T\u00a0cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia","volume":"122","author":"Mardiros","year":"2013","journal-title":"Blood"},{"issue":"1","key":"2023082419243871700_bib138","doi-asserted-by":"crossref","first-page":"6436","DOI":"10.1038\/s41467-021-26683-0","article-title":"Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia","volume":"12","author":"El Khawanky","year":"2021","journal-title":"Nat Commun"},{"issue":"1","key":"2023082419243871700_bib139","doi-asserted-by":"crossref","first-page":"e172","DOI":"10.1097\/HS9.0000000000000172","article-title":"CAR T cells: a snapshot on the growing options to design a CAR","volume":"3","author":"Holzinger","year":"2019","journal-title":"HemaSphere"},{"issue":"4","key":"2023082419243871700_bib140","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J"},{"issue":"5","key":"2023082419243871700_bib141","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/s41568-022-00441-w","article-title":"CRISPR in cancer biology and therapy","volume":"22","author":"Katti","year":"2022","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"2023082419243871700_bib142","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41568-020-00323-z","article-title":"Recent advances and discoveries in the mechanisms and functions of CAR T cells","volume":"21","author":"Larson","year":"2021","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"2023082419243871700_bib143","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1007\/s12185-021-03209-4","article-title":"Engineering the next generation of CAR-NK immunotherapies","volume":"114","author":"Biederst\u00e4dt","year":"2021","journal-title":"Int J Hematol"},{"issue":"8","key":"2023082419243871700_bib144","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/s41591-021-01436-0","article-title":"CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial","volume":"27","author":"Spiegel","year":"2021","journal-title":"Nat Med"},{"issue":"10","key":"2023082419243871700_bib145","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1038\/s41591-021-01497-1","article-title":"CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial","volume":"27","author":"Cordoba","year":"2021","journal-title":"Nat Med"},{"issue":"6","key":"2023082419243871700_bib146","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1038\/s41375-018-0075-3","article-title":"Compound CAR T-cells as a double-pronged approach for treating acute myeloid leukemia","volume":"32","author":"Petrov","year":"2018","journal-title":"Leukemia"},{"issue":"7","key":"2023082419243871700_bib147","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1038\/s41375-021-01253-x","article-title":"T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments","volume":"35","author":"Daver","year":"2021","journal-title":"Leukemia"},{"issue":"3","key":"2023082419243871700_bib148","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.ccell.2019.02.003","article-title":"Logic-gated ROR1 chimeric antigen receptor expression rescues T cell-mediated toxicity to normal tissues and enables selective tumor targeting","volume":"35","author":"Srivastava","year":"2019","journal-title":"Cancer Cell"},{"issue":"18","key":"2023082419243871700_bib149","doi-asserted-by":"crossref","first-page":"126345","DOI":"10.1172\/jci.insight.126345","article-title":"ROR1-CAR T cells are effective against lung and breast cancer in advanced microphysiologic 3D tumor models","volume":"4","author":"Wallstabe","year":"2019","journal-title":"JCI Insight"},{"issue":"1","key":"2023082419243871700_bib150","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/s41467-021-21078-7","article-title":"Engineering advanced logic and distributed computing in human CAR immune cells","volume":"12","author":"Cho","year":"2021","journal-title":"Nat Commun"},{"issue":"13 suppl","key":"2023082419243871700_bib151","doi-asserted-by":"crossref","first-page":"LB028","DOI":"10.1158\/1538-7445.AM2021-LB028","article-title":"Abstract LB028: Development of logic-gated CAR-NK cells to reduce target-mediated healthy tissue toxicities","volume":"81","author":"Gonzalez","year":"2021","journal-title":"Cancer Res"},{"key":"2023082419243871700_bib152","first-page":"4S1","article-title":"Precise targeting of AML with first-in-class OR\/NOT logic-gated gene circuits in CAR-NK Cells","volume":"29","author":"Garrison","year":"2021","journal-title":"Presented at the 24th ASGCT Annual Meeting Abstract 77"},{"issue":"6","key":"2023082419243871700_bib153","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1158\/2643-3230.BCD-20-0208","article-title":"NOT-gated CD93 CAR T cells effectively target AML with minimized endothelial cross-reactivity","volume":"2","author":"Richards","year":"2021","journal-title":"Blood Cancer Discov"},{"issue":"suppl 1","key":"2023082419243871700_bib154","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1182\/blood-2021-149263","article-title":"\u201cIF-better\u201d gating: combinatorial targeting and synergistic signaling for enhanced CAR T cell Efficacy","volume":"138","author":"Haubner","year":"2021","journal-title":"Blood"},{"key":"2023082419243871700_bib155","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.omto.2020.04.009","article-title":"Rapidly switchable universal CAR-T cells for treatment of CD123-positive leukemia","volume":"17","author":"Loff","year":"2020","journal-title":"Mol Ther Oncolytics"},{"issue":"7","key":"2023082419243871700_bib156","doi-asserted-by":"crossref","first-page":"7487","DOI":"10.18632\/oncotarget.23556","article-title":"Retargeting of UniCAR T cells with an in\u00a0vivo synthesized target module directed against CD19 positive tumor cells","volume":"9","author":"Bachmann","year":"2017","journal-title":"Oncotarget"},{"issue":"8","key":"2023082419243871700_bib157","doi-asserted-by":"crossref","first-page":"e458","DOI":"10.1038\/bcj.2016.61","article-title":"Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts","volume":"6","author":"Cartellieri","year":"2016","journal-title":"Blood Cancer J"},{"issue":"1","key":"2023082419243871700_bib158","doi-asserted-by":"crossref","first-page":"1945804","DOI":"10.1080\/2162402X.2021.1945804","article-title":"Evaluation of switch-mediated costimulation in trans on universal CAR-T cells (UniCAR) targeting CD123-positive AML","volume":"10","author":"Meyer","year":"2021","journal-title":"OncoImmunology"},{"issue":"1","key":"2023082419243871700_bib159","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1038\/s41598-020-59082-4","article-title":"\u201cUniCAR\u201d-modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumour cells","volume":"10","author":"Mitwasi","year":"2020","journal-title":"Sci Rep"},{"issue":"22","key":"2023082419243871700_bib160","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1182\/blood.2020009759","article-title":"Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed\/refractory AML","volume":"137","author":"Wermke","year":"2021","journal-title":"Blood"},{"issue":"374","key":"2023082419243871700_bib161","doi-asserted-by":"crossref","first-page":"eaaj2013","DOI":"10.1126\/scitranslmed.aaj2013","article-title":"Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells","volume":"9","author":"Qasim","year":"2017","journal-title":"Sci Transl Med"},{"issue":"3","key":"2023082419243871700_bib162","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","article-title":"\u2018Off-the-shelf\u2019 allogeneic CAR T cells: development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat Rev Drug Discov"},{"issue":"suppl 1","key":"2023082419243871700_bib163","doi-asserted-by":"crossref","first-page":"S157","DOI":"10.1016\/S1525-0016(16)33206-3","article-title":"397. Allogenic CAR T-cells targeting CD123 effectively eliminate myeloid leukemia cells","volume":"24","author":"Galetto","year":"2016","journal-title":"Mol Ther"},{"issue":"2","key":"2023082419243871700_bib164","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/leu.2017.226","article-title":"Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity","volume":"32","author":"Liu","year":"2018","journal-title":"Leukemia"},{"issue":"15","key":"2023082419243871700_bib165","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1158\/1078-0432.CCR-16-2981","article-title":"Successful transfer of umbilical cord blood CD34+ hematopoietic stem and progenitor-derived NK cells in older acute myeloid leukemia patients","volume":"23","author":"Dolstra","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2023082419243871700_bib166","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.ygyno.2020.03.020","article-title":"Harnessing natural killer cells for the treatment of ovarian cancer","volume":"157","author":"Hoogstad-van Evert","year":"2020","journal-title":"Gynecol Oncol"},{"issue":"20","key":"2023082419243871700_bib167","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1182\/blood.2020006619","article-title":"CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas","volume":"136","author":"Gang","year":"2020","journal-title":"Blood"},{"issue":"6","key":"2023082419243871700_bib168","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1182\/blood.2019000621","article-title":"Pluripotent stem cell-derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity","volume":"135","author":"Zhu","year":"2020","journal-title":"Blood"},{"issue":"2","key":"2023082419243871700_bib169","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.stem.2018.06.002","article-title":"Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity","volume":"23","author":"Li","year":"2018","journal-title":"Cell Stem Cell"},{"issue":"2","key":"2023082419243871700_bib170","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.stem.2020.05.008","article-title":"Metabolic reprograming via deletion of CISH in human iPSC-derived NK cells promotes in\u00a0vivo persistence and enhances anti-tumor activity","volume":"27","author":"Zhu","year":"2020","journal-title":"Cell Stem Cell"},{"issue":"suppl_3","key":"2023082419243871700_bib171","doi-asserted-by":"crossref","first-page":"iii51","DOI":"10.1093\/neuonc\/nox036.186","article-title":"P07.01 The CAR2BRAIN study: a monocentric phase I trial with ErbB2-specific NK-92\/5.28.z cells in recurrent glioblastoma","volume":"19","author":"Burger","year":"2017","journal-title":"Neuro-oncol"},{"issue":"7","key":"2023082419243871700_bib172","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1111\/jcmm.12810","article-title":"CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies","volume":"20","author":"Romanski","year":"2016","journal-title":"J\u00a0Cell Mol Med"},{"issue":"1","key":"2023082419243871700_bib173","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1158\/2159-8290.CD-20-0556","article-title":"Outlook for new CAR-based therapies with a focus on CAR NK cells: what lies beyond CAR-engineered T cells in the race against cancer","volume":"11","author":"Daher","year":"2021","journal-title":"Cancer Discov"},{"issue":"2","key":"2023082419243871700_bib174","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/bjh.17186","article-title":"Chimeric antigen receptor (CAR) natural killer (NK)-cell therapy: leveraging the power of innate immunity","volume":"193","author":"Rafei","year":"2021","journal-title":"Br J Haematol"},{"issue":"6","key":"2023082419243871700_bib175","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 1","key":"2023082419243871700_bib176","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1182\/blood-2021-151185","article-title":"Safety and efficacy of FT596, a first-in-class, multi-antigen targeted, off-the-shelf, iPSC-derived CD19 CAR NK cell therapy in relapsed\/refractory B-cell lymphoma","volume":"138","author":"Bachanova","year":"2021","journal-title":"Blood"},{"issue":"5","key":"2023082419243871700_bib177","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1182\/blood.2020007748","article-title":"Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells","volume":"137","author":"Daher","year":"2021","journal-title":"Blood"},{"issue":"13","key":"2023082419243871700_bib178","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1158\/1078-0432.CCR-21-0164","article-title":"Combining AFM13, a bispecific CD30\/CD16 antibody, with cytokine-activated blood and cord blood-derived NK cells facilitates CAR-like responses against CD30+ malignancies","volume":"27","author":"Kerbauy","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2023082419243871700_bib179","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1182\/blood.V95.6.2098","article-title":"A\u00a0recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes","volume":"95","author":"L\u00f6ffler","year":"2000","journal-title":"Blood"},{"issue":"8","key":"2023082419243871700_bib180","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1200\/JCO.19.02657","article-title":"Anti-B-cell maturation antigen BiTE molecule AMG 420 induces responses in multiple myeloma","volume":"38","author":"Topp","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"2023082419243871700_bib181","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1038\/leu.2016.388","article-title":"A\u00a0novel BCMA\/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in\u00a0vitro and in\u00a0vivo [published correction appears in Leukemia. 2017;31(10):2278]","volume":"31","author":"Hipp","year":"2017","journal-title":"Leukemia"},{"issue":"7","key":"2023082419243871700_bib182","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/j.cell.2019.04.041","article-title":"Multifunctional natural killer cell engagers targeting NKp46 trigger protective tumor immunity","volume":"177","author":"Gauthier","year":"2019","journal-title":"Cell"},{"issue":"12","key":"2023082419243871700_bib183","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1007\/s00262-021-03008-0","article-title":"CD16xCD33 bispecific killer cell engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL [published correction appears in Cancer Immunol Immunother. 2021;70(12):3709]","volume":"70","author":"Reusing","year":"2021","journal-title":"Cancer Immunol Immunother"},{"issue":"suppl 1","key":"2023082419243871700_bib184","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1182\/blood-2018-99-109762","article-title":"A\u00a0phase 1 first-in-human study of AMG 330, an anti-CD33 bispecific T-cell engager (BiTE\u00ae) antibody construct, in relapsed\/refractory acute myeloid leukemia (R\/R AML)","volume":"132","author":"Ravandi","year":"2018","journal-title":"Blood"},{"issue":"1","key":"2023082419243871700_bib185","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s40425-018-0432-9","article-title":"CD33\/CD3-bispecific T-cell engaging (BiTE\u00ae) antibody construct targets monocytic AML myeloid-derived suppressor cells","volume":"6","author":"Jitschin","year":"2018","journal-title":"J\u00a0Immunother Cancer"},{"issue":"8","key":"2023082419243871700_bib186","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/nm.3910","article-title":"NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma","volume":"21","author":"Rapoport","year":"2015","journal-title":"Nat Med"},{"issue":"3","key":"2023082419243871700_bib187","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1182\/blood-2013-01-478164","article-title":"Enhanced-affinity murine T-cell receptors for tumor\/self-antigens can be safe in gene therapy despite surpassing the threshold for thymic selection","volume":"122","author":"Schmitt","year":"2013","journal-title":"Blood"},{"issue":"22","key":"2023082419243871700_bib188","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1182\/blood.V128.22.1001.1001","article-title":"EBV-specific donor cells transduced to express a high-affinity WT1 TCR can prevent recurrence in post-HCT patients with high-risk AML","volume":"128","author":"Chapuis","year":"2016","journal-title":"Blood"},{"issue":"7","key":"2023082419243871700_bib189","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1038\/s41591-019-0472-9","article-title":"T\u00a0cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant","volume":"25","author":"Chapuis","year":"2019","journal-title":"Nat Med"},{"issue":"2","key":"2023082419243871700_bib190","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41591-021-01621-1","article-title":"HLA-independent T cell receptors for targeting tumors with low antigen density","volume":"28","author":"Mansilla-Soto","year":"2022","journal-title":"Nat Med"},{"issue":"10","key":"2023082419243871700_bib191","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1182\/blood-2017-05-784306","article-title":"A\u00a0new tool for rapid and reliable diagnosis of HLA loss relapses after HSCT","volume":"130","author":"Ahci","year":"2017","journal-title":"Blood"},{"issue":"147","key":"2023082419243871700_bib192","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3389\/fimmu.2020.00147","article-title":"Mechanisms of leukemia immune evasion and their role in relapse after haploidentical hematopoietic cell transplantation","volume":"11","author":"Rovatti","year":"2020","journal-title":"Front Immunol"},{"issue":"11","key":"2023082419243871700_bib193","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1016\/j.bbmt.2017.09.009","article-title":"Choosing the alternative","volume":"23","author":"Vago","year":"2017","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/141\/1\/22\/2073317\/blood_bld-2021-012411-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/141\/1\/22\/2073317\/blood_bld-2021-012411-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T19:27:11Z","timestamp":1692905231000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/141\/1\/22\/485176\/How-I-treat-high-risk-acute-myeloid-leukemia-using"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,5]]},"references-count":193,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1,5]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2021012411","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,5]]}}}